The first reason someone cares about biotech might be their skin, their hair, or the strength they want to keep as they age. @ArtemyShumskiy argues that these desires could help solve longevity biotech’s funding problem. He points to GLP-1s as evidence of the market for outcomes people want and will pay for. The proposal is to make those outcomes the starting point for drug development. Define the improvement in strength, cognition or metabolic health, then work backwards through the biology. That gives researchers a clear goal and investors a clearer picture of demand. This is why we’re looking at consumer biotech as an entry point for Bio Protocol. People can help fund something they want to use and follow what the experiments actually show.